RecruitingPhase 1Drug trialA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasThis is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.